- Home
- LDI vs MNMD Comparison
LDI vs MNMD Comparison
Compare LDI & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- MNMD
- Stock Information
- Founded
- LDI 2010
- MNMD 2019
- Country
- LDI United States
- MNMD United States
- Employees
- LDI N/A
- MNMD N/A
- Industry
- LDI Finance: Consumer Services
- MNMD Pharmaceuticals and Biotechnology
- Sector
- LDI Finance
- MNMD Health Care
- Exchange
- LDI Nasdaq
- MNMD Nasdaq
- Market Cap
- LDI 954.8M
- MNMD 811.9M
- IPO Year
- LDI 2021
- MNMD N/A
- Fundamental
- Price
- LDI $2.91
- MNMD $11.98
- Analyst Decision
- LDI Sell
- MNMD Strong Buy
- Analyst Count
- LDI 3
- MNMD 6
- Target Price
- LDI $2.30
- MNMD $26.50
- AVG Volume (30 Days)
- LDI 16.0M
- MNMD 1.7M
- Earning Date
- LDI 11-04-2025
- MNMD 11-06-2025
- Dividend Yield
- LDI N/A
- MNMD N/A
- EPS Growth
- LDI N/A
- MNMD N/A
- EPS
- LDI N/A
- MNMD N/A
- Revenue
- LDI $1,124,074,000.00
- MNMD N/A
- Revenue This Year
- LDI $19.82
- MNMD N/A
- Revenue Next Year
- LDI $17.78
- MNMD N/A
- P/E Ratio
- LDI N/A
- MNMD N/A
- Revenue Growth
- LDI 27.06
- MNMD N/A
- 52 Week Low
- LDI $1.01
- MNMD $4.70
- 52 Week High
- LDI $5.05
- MNMD $12.76
- Technical
- Relative Strength Index (RSI)
- LDI 48.66
- MNMD 63.78
- Support Level
- LDI $2.87
- MNMD $8.77
- Resistance Level
- LDI $3.14
- MNMD $12.76
- Average True Range (ATR)
- LDI 0.29
- MNMD 0.81
- MACD
- LDI -0.12
- MNMD 0.21
- Stochastic Oscillator
- LDI 2.68
- MNMD 78.18
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).